Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)

類似資料

• Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults
  著者:: Robin H. Lachmann, 等
  出版事項: (2023-04-01)
• Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt: A prospective, observational cohort study with an interventional subgroup
  著者:: Nehal Abdelaziz Arafa, 等
  出版事項: (2026-03-01)
• Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomyelinase Deficiency in Taiwan
  著者:: Hsu‐Heng Lin, 等
  出版事項: (2026-02-01)
• Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency
  著者:: Eva M. Raebel, 等
  出版事項: (2024-02-01)
• Real-life impacts of olipudase alfa: experiences of adults receiving enzyme replacement therapy for acid sphingomyelinase deficiency—results from an international survey study
  著者:: Adel Sabet Morsy, 等
  出版事項: (2025-09-01)